MedTrace Logo

Evaluation of Vitoss With and Without BMA for Benign Cavitary Lesions

NCT02165943 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-06-18

No results posted yet for this study

Summary

This is a retrospective, two-arm study reviewing the healing of cavitary defects in patients treated with Vitoss alone versus those treated with Vitoss with bone marrow aspirate (BMA). There will be a prospective follow-up visit at 24+ months to evaluate lont-term healing in patients identified during the retrospective portion of the study. It is thought that the inclusion of BMA will facilitate the resorption of the graft material, leading to better long-term bone healing.

Conditions

  • Bone Diseases

Interventions

DEVICE

Vitoss

Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.

Sponsors & Collaborators

  • Orthovita d/b/a Stryker

    lead INDUSTRY

Principal Investigators

  • Timothy Damron, MD · State University of New York - Upstate Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02165943 on ClinicalTrials.gov